C
Constance Williams
Researcher at New York University
Publications - 58
Citations - 6063
Constance Williams is an academic researcher from New York University. The author has contributed to research in topics: Epitope & Monoclonal antibody. The author has an hindex of 33, co-authored 58 publications receiving 5710 citations. Previous affiliations of Constance Williams include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes,Peter B. Gilbert,M. Juliana McElrath,Susan Zolla-Pazner,Georgia D. Tomaras,S. Munir Alam,David T. Evans,David C. Montefiori,Chitraporn Karnasuta,Ruengpueng Sutthent,Hua-Xin Liao,Anthony L. DeVico,George K. Lewis,Constance Williams,Abraham Pinter,Youyi Fong,Holly Janes,Allan C. deCamp,Yunda Huang,Mangala Rao,Erik Billings,Nicos Karasavvas,Merlin L. Robb,Viseth Ngauy,Mark de Souza,Robert Paris,Guido Ferrari,Robert T. Bailer,Kelly A. Soderberg,Charla Andrews,Phillip W. Berman,Nicole Frahm,Stephen C. De Rosa,Michael D. Alpert,Nicole L. Yates,Xiaoying Shen,Richard A. Koup,Punnee Pitisuttithum,Jaranit Kaewkungwal,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Nelson L. Michael,Jerome H. Kim +42 more
TL;DR: V vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.
Journal ArticleDOI
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env
Young Do Kwon,Marie Pancera,Priyamvada Acharya,Ivelin S. Georgiev,Emma T. Crooks,Jason Gorman,M. Gordon Joyce,Miklos Guttman,Xiaochu Ma,Sandeep Narpala,Cinque Soto,Daniel S. Terry,Yongping Yang,Tongqing Zhou,Goran Ahlsen,Robert T. Bailer,Michael Chambers,Gwo-Yu Chuang,Nicole A. Doria-Rose,Aliaksandr Druz,Mark A. Hallen,Adam Harned,Tatsiana Kirys,Mark K. Louder,Sijy O'Dell,Gilad Ofek,Keiko Osawa,Madhu Prabhakaran,Mallika Sastry,Guillaume Stewart-Jones,Jonathan Stuckey,Paul V. Thomas,Tishina Tittley,Constance Williams,Baoshan Zhang,Hong Zhao,Zhou Zhou,Bruce R. Donald,Lawrence K. Lee,Susan Zolla-Pazner,Ulrich Baxa,Arne Schön,Ernesto Freire,Lawrence Shapiro,Kelly K. Lee,James Arthos,James B. Munro,Scott C. Blanchard,Walther Mothes,James M. Binley,Adrian B. McDermott,John R. Mascola,Peter D. Kwong +52 more
TL;DR: Antigenicity-guided structural design can be used both to delineate mechanism and to fix conformation, with DS-Env trimers in virus-like-particle and soluble formats providing a new generation of vaccine antigens.
Journal ArticleDOI
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
Susan Zolla-Pazner,Allan C. deCamp,Peter B. Gilbert,Constance Williams,Nicole L. Yates,William T. Williams,Robert Howington,Youyi Fong,Daryl E. Morris,Kelly A. Soderberg,Carmela Irene,Charles Reichman,Abraham Pinter,Robert Parks,Punnee Pitisuttithum,Jaranit Kaewkungwal,Supachai Rerks-Ngarm,Sorachai Nitayaphan,Charla Andrews,Robert J. O'Connell,Zhi Yong Yang,Gary J. Nabel,Jerome H. Kim,Nelson L. Michael,David C. Montefiori,Hua-Xin Liao,Barton F. Haynes,Georgia D. Tomaras +27 more
TL;DR: Levels of vaccine-induced IgG Abs recognizing V1V2 regions from multiple HIV-1 subtypes, and presented on different scaffolds constitute inverse correlates of risk for HIV- 1 infection in the RV144 vaccine trial.
Journal ArticleDOI
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.
Anthony J. Conley,M K Gorny,Joseph Kessler,Lynn J. Boots,M Ossorio-Castro,S Koenig,D W Lineberger,Emilio A. Emini,Constance Williams,Susan Zolla-Pazner +9 more
TL;DR: The study demonstrated that neutralization of primary HIV-1 isolates is possible if mediated by an appropriate antibody, and confirmed that this determinant is commonly expressed by virus isolates belonging to the subtype (clade) B sequence classification.
Journal ArticleDOI
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
Miroslaw K. Gorny,John P. Moore,A J Conley,S. Karwowska,Joseph Sodroski,Constance Williams,Sherri Burda,L J Boots,Susan Zolla-Pazner +8 more
TL;DR: 697-D and a human anti-V3 MAb, 447-52-D, displayed similar potency in neutralizing primary isolates, indicating that the V2 region of gp120, like the V3 region and the CD4-binding domain, can induce potent neutralizing antibodies against HIV-1 in humans.